Top Ten 2026: Redefining Public Health Policy Podcast Por  arte de portada

Top Ten 2026: Redefining Public Health Policy

Top Ten 2026: Redefining Public Health Policy

Escúchala gratis

Ver detalles del espectáculo

Based on AHLA's annual Health Law Connections article, this special ten-part series brings together thought leaders from across the health law field to discuss the top ten issues of 2026. In the third episode, Anna M. Lozoya, General Counsel, Physician Alliance Group PC, speaks with Miranda Franco, Senior Policy Advisor, Holland & Knight LLP, about the forces currently shaping public health policy and why 2026 marks a turning point. They discuss the advancement of the administration’s “Make America Healthy Again” agenda through the Center for Medicare and Medicaid Innovation, drug pricing, vaccine policy, and where health systems can devote resources based on current public health trends. From AHLA’s In-House Counsel Practice Group.

Watch this episode: https://www.youtube.com/watch?v=_aCBcqNZRJg

Read AHLA's Top Ten 2026 article: https://www.americanhealthlaw.org/content-library/connections-magazine/article/a879dda5-35f9-46fb-ad45-1b0799343d74/Health-Law-Forecast-2026

Access all episodes in AHLA's Top Ten 2026 podcast series: https://www.americanhealthlaw.org/education-events/speaking-of-health-law-podcasts/top-ten-issues-in-health-law-podcast-series

Learn more about AHLA’s In-House Counsel Practice Group: https://www.americanhealthlaw.org/practice-groups/practice-groups/in-house-counsel

Essential Legal Updates, Now in Audio

AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Comprehensive members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast.

Stay At the Forefront of Health Legal Education

Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.

Todavía no hay opiniones